, Tracking Stock Market Picks
Enter Symbol:
Elan Corporation, Plc (ELN) [hlAlert]

down 31.36 %

Elan Corporation, Plc (ELN) rated Buy by Merriman Curhan Ford

Posted on: Wednesday,  Jun 11, 2008  8:25 AM ET by Merriman Curhan Ford

Merriman Curhan Ford rated Buy Elan Corporation, Plc (NYSE: ELN) on 06/11/2008, when the stock price was $26.40.
Since then, Elan Corporation, Plc has lost 31.36% as of 12/18/2013's recent price of $18.12.
If you would have followed this Merriman Curhan Ford's recommendation on ELN, you would have lost 31.36% of your investment in 2016 days.

Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its principal research and development, manufacturing and marketing facilities are located in Ireland and the United States. Elan?s operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain. EDT focuses on the specialty pharmaceutical industry, including specialized drug delivery and manufacturing. In September 2009, the Company and Johnson & Johnson announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer`s Immunotherapy Program (AIP).

We occupy a unique niche among our investment banking peers: we offer our clients both traditional sell-side equity research and primary market research, and we focus on high-potential sectors such as CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. Our institutional and corporate clients get the best of both worlds: expertise from our analysts and access to experts through our Panel Intelligence platform.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/11/2008 8:25 AM Buy
as of 12/24/2008
1 Week down  -4.85 %
1 Month down  -6.88 %
3 Months down  -24.56 %
1 YTD down  -78.48 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy